Impact of Phlebotomy on Quality of Life in Low-Risk Polycythemia Vera.
Nathan VisweshwarBradley FletcherMichael JaglalDamian A LaberAnkita PatelJennifer EatridesGeetha Rajasekharan RathnakumarKeshav Visweswaran IyerIrmel AyalaArumugam ManoharanPublished in: Journal of clinical medicine (2024)
Polycythemia vera is an indolent myeloproliferative disorder that predisposes patients to venous and arterial thrombosis and can transform into myelofibrosis and acute myeloid leukemia. Consistent phlebotomy prevents life-threatening cerebrovascular and coronary artery disease and prolongs survival in low-risk polycythemia vera (patients under 60 years without thrombosis). However, despite its effectiveness in preventing serious complications, phlebotomy does not necessarily enhance the quality of life (QoL). This review assesses QoL issues associated with low-risk PV, explores alternative management strategies such as erythrocytapheresis, and discusses the roles of hydroxyurea, peginterferon, ruxolitinib, and other novel agents in potentially improving disease management and patient outcomes.
Keyphrases
- end stage renal disease
- acute myeloid leukemia
- ejection fraction
- newly diagnosed
- pulmonary embolism
- randomized controlled trial
- peritoneal dialysis
- patient reported outcomes
- mouse model
- percutaneous coronary intervention
- acute lymphoblastic leukemia
- cardiovascular events
- coronary artery bypass grafting
- aortic valve